

# MITIGATION STRATEGIES FOR NITROSAMINE DRUG SUBSTANCE RELATED IMPURITIES: QUALITY AND BIOEQUIVALENCE CONSIDERATIONS FOR GENERICS

## Session 3: Impact of Reformulation on the Bioequivalence of Generic Products and FDA Perspectives on Reformulated Generics

### *Presenters:*

**Chris Bode, PhD**

**Sook Wah Yee, MPharm, PhD**

**Fang Wu, PhD**

**Dongmei Lu, PhD**

Vice President of Scientific Affairs, Pharmaron

Assistant Adjunct Professor, University of California, San Francisco

Senior Pharmacologist, DQMM, ORS, OGD, CDER, FDA

Policy Lead, OPPQ, OPQ, CDER, FDA

### *Moderator:*

**Khondoker Alam, PhD**

### *Panelists:*

**Andre Raw, PhD**

**Bhagwant Rege, PhD**

**Bing Li, PhD**

**Chris Bode, PhD**

**Dongmei Lu, PhD**

**Fang Wu, PhD**

**Lanyan (Lucy) Fang, PhD**

**Sook Wah Yee, MPharm, PhD**

Senior Staff Fellow, DQMM, ORS, OGD, CDER, FDA

Associate Director for Science and Communication, OLDP, OPQ, CDER, FDA

Division Director, DB, ONDP, OPQ, CDER, FDA

Associate Director for Science, OB, OGD, CDER, FDA

Vice President of Scientific Affairs, Pharmaron

Policy Lead, OPPQ, OPQ, CDER, FDA

Senior Pharmacologist, DQMM, ORS, OGD, CDER, FDA

Deputy Director, DQMM, ORS, OGD, CDER, FDA

Assistant Adjunct Professor, University of California, San Francisco